Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. And welcome to the BioAtla First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.

conference your the from Bruce turn Advisors. LifeSci now over host, to Mackle I’ll Bruce. you, Thank

begin. may You

Bruce Mackle

Thank you, Jay good Financial phone and operator, and and Officer. from on me Co-Founder; BioAtla the today are Waldron, Dr. Richard Short, CEO, afternoon, Chairman, Chief everyone. With

Sievers, Vice Rick Following Eric President, will Jay Martin, and Commercial a Operations; Philippe and short Officer; call, of Clinical Strategy, Medical today's and Sheri for Q&A. Development Chief Dr. Chief Lydick, Senior join

a afternoon, business A website. for of available BioAtla quarter released March this the is and ended results Earlier first update financial release company's the XXst, copy on XXXX. the press

BioAtla's Before we potential selective plans collaborations, during forward-looking conduct, with and made will R&D be and regulatory and product begin, statements submissions, G&A and licensing, about include regulatory future timing trials, whether results, partnerships, registrational, other will like progress regarding I'd our statements, trials including everyone and limited our of of business expenses. expectations that conference potentially and not clinical clinical call meetings, remind and trials, and sufficiency prospects, our path equivalents cash for regulatory cash this approval data our updates, but to the strategic regarding dosing to respect trials, statements the research expected development plans clinical candidates; in clinical programs, expectations and our enrollment potential and to

can the the to XX-Q. cause These statements filings results that including report the are described subject with SEC, quarterly most on actual uncertainties risks, to materially and made and various differ recent assumptions Form are in

XXth, to such except future events only which these on disclaims statements to reliance by any as circumstances, obligation undue statements, update place to not BioAtla cautioned or required of May today, and are law. speak reflect as information, XXXX, You forward-looking

call Jay the to With Jay? turn over Short. like to that, I'd

Jay Short

quarter and to earnings for first XXXX Thank joining us our you, Bruce everyone BioAtla's for thanks call.

key a points an quarter last made like I call on to first on in few progress, our would Before I quarter March. our update provide reiterate

development cells, of active platform order cells while a the As in tumor BioAtla needs in using patients' conditionally to is with unmet reminder, therapies CAB, for lives. improve novel leader in urgent improved attacking oncology selectivity avoiding healthy a the address to proprietary inventor and biologics,

across We progress our product Phase multiple needs. ongoing made significant solid BAXXXXand last tumor two year trials unmet types our high BAXXXX, first-in-class for with X targeting candidates, CAB-ADC latest-stage medical

we track As are now our XXXX, little continue over milestones. and quarter guided are we positive to one on a trajectory full into achieve our recently

innovative on cell CAB-RORX-ADCs, our and development and programs, and across further leveraging our focused including types, applicability immuno-oncology naked our T bispecific CAB-CTLA-X, of engager. targeted the the stage EpCAM advancing clinical of first CDX several AXL broad remain CAB, technology We clinical antibody CAB antibody dual CAB

our to to may related to what that Additional on details available provide you. as I'm be helpful part are updated website of our going presentation company

on small We shared have Last to shared cases, incremental data shift sets data programs. interim our mature across sample responses several that more in responses. sizes far strategic from and updates meeting date targeted study are clinical our quarter, so promising exceeding providing I releasing our to

our As that studies. a parameters likelihood maximize study the to provide goal to registrational allow successful to of us sufficient reminder, our data is for company's X, set Phase potentially

of including found website. our Additionally, corporate presentation more in regimens. these be I dose updated the frequent for our rationale the can dose-intensive last summary regimens discussed current quarter, A on

activity improved improvement the we of or CAB-ADCs response having exposure our risk potential our in while in differentiated safety for to X trials similar Phase FDA our profile on benefit UPS-related maximize as even our aim well Based X as further analysis antitumor interactions, profile. part

BAXXXX the about non-small to excited encouraging study. part X Phase Previously, X shared lung multiple part X for cell BAXXXX and Phase on we X asset, our our BAXXX, continue indications. study cancer sarcoma data lead our be partial We interim

and our financial the move clinical quarter first to now updates Let's XXXX. for operational

First, strategy. I will sarcoma reiterate our BAXXXX Phase X our and sarcoma study overall

Phase in studies, a ongoing UPS. X potentially including We registrational study are advancing in BAXXXX sarcoma

As the is aggressive and with nearly it unmet one representing UPS, recurrence sarcomas. XX% all most of in of a recap largest of tissue need soft rates, high subtypes the sarcoma

specific opportunity is standalone there treatments Without commercial a approved significant for a UPS, as indication.

UPS progression shown results strong promising lack a disease of execution activity, BAXXXX and of safety and We with in antitumor continued to-date. profile differentiated have

months. objective free eight Additionally, or of response we ORR of median XX%; response a overall PFS duration survival rate or over months and have observed progression of exceeding an XX

Based feedback differentiated around registrational the year and on potentially X we the portion of of study last design, FDA continued trial. together part with these safety encouraging profile the the results, from the initiated

XX greater to The the dosing equal are randomized XX% or X:X TmPS being the first than with between regimens. patients or XQXW XQXW

treated ORR patients additional will approximately Following regimen. the on primary be selected patients based study. an to the this, we XX the XX at enroll plan the Overall, to at dosing selected complete endpoint efficacy dose

UPS company. BioAtla, represents commercial plan indication for into stage transition as solid a a we early with the

we regimen track enroll data anticipated readout with the are the leiomyosarcoma in the and UPS, in this using addition half on In continue to year. second cohort to XQXW of dosing

safety continues in X generally we the with consistent With with to across to the profile Phase observed doses, sarcoma regards well safety be X. across profile all profile BAXXXX Phase the subtypes, tolerated

unmet has potentially of expanding sarcoma real to treat sarcoma other in We XX,XXX $X per Ultimately, up patients and BAXXXX need. our year believe over subtypes. see sarcoma also to worldwide this time revenue footprint the over include billion in potential generate area we value high to in

X Phase data non-small with regimen. the earlier presented Regarding the QXW dosing we about in we enthusiastic cancer, be this our continue lung to year cell AXL-positive multi-refractory BAXXXX study

for have and landscape beyond approximately in competitive to rates immune scanned XX% on four months. PFS XX% is who line particularly progress of inhibitors, Currently, These options overall in the treatment the ORRs patients suboptimal of setting. and second patients checkpoint

previously study X in a experienced or ALK in of Phase EGFR, X cancer inhibitors. failure non-small PD-LX, As either PD-X, have of cell patients a is ongoing who lung reminder, part AXL-positive

PD-X far potentially reported population response failure exceeded we and efficacy competitive is preliminary the on So response have three of part and rate This highly in seen, our to of forward lines the Phase monotherapy that for study. an therapy. X study, ORR prior targeted a XX% have of with registrational moving average, as the

We Phase continue to a a lines be patients in relevant commercially a population, treating particularly view of highly with part response believe BAXXXX above earlier X. will observed in X in those multi-refractory well patient

X using of this the on regimens for X second enroll part addition, of with all data for the the year. half anticipated dosing continues In readout study Phase regimen frequent dose-intensive to more track

of to half on part meeting BAXXXX in design to a anticipated X this in half request our study non-small year, with half year, non-small feedback FDA the second lung the part the timeline this lung allowing cancer overall the first the maintaining lung X potentially remain to submit cell education. cell track cancer registrational of the second of in in for us year the of Phase study We cell non-small initiate cancer X for Phase X this development

at AXL potential cancer non-small with plus mentioned, annually the approximately there billion of estimate previously $X.X second approximately add to line indication have in we worldwide of peak. over patients the AXL. that positive $X express We billion XXX,XXX lung are XX% cell worldwide in patients revenue to addressable As

to significant to the that believe Considering sarcoma we indications, non-small a become the asset for cancer lung only continue has BAXXXX potential commercial cell BioAtla.

medical greater unmet Of of be best-in-class filling a for significant BAXXXX number need. thus a who has that fail the the lines importance of to even is therapy, treatment potential patients significant multiple

clinical To trial round patients we anticipate out the are ovarian second our an of investigator-initiated CAB-ADC year. cancer. patients BAXXXX Phase in platinum-resistant of with in half multicenter ongoing interim this consisting is The track, trial IIT program, we X data on supporting or XX and

treatment lead Now, in candidate, of ADC. turning the BAXXXX, Currently, of X is a second CAB-ADC CAB-RORX subject four indications. trials Phase to BAXXXX our product the

other a therapy in the a company reminder, clinic no RORX. targeting As has

So,, cell our to tumors. lung more response a we exposure treatment the RORX-positive in We solid tumors study. dose-intensity a similar of regimen have form Phase have to X frequent cancer analysis conducted the RORX-positive non-small potential first-in-class for

mentioned this analysis, UPS which X utilizes on BAXXXX X strategy a to study our earlier. Based Phase I similar part

as intensity half XQXW this data in for second of continuing frequent track We are interim the of readout to on more dose the enroll year. patients with planned regimen

Regarding in the have evaluable previously complete in response patients identified Phase failure with biopsy. additional an patients following trial who our X an therapy melanoma IHC the liquid experienced using are of patient screening PD-X validated we assay,

the is using an enrolled to identified tumors Although us which now RORX-positve in to assay, we of We anticipate this additional enroll year. liquid RORX-positve we half haven't second the increased biopsy have date, enrollment patients. successfully patients allowing

with combination have who study of In or ongoing failure addition, in X alone and therapy. patients our neck PD-X is Phase previously experienced therapy head in platinum

continued Last observed last over first study. with in for to and enroll XX% quarter, our high, RORX line the patients is the in of we expectations. announced we Since positivity and achievement patient rate quarter,

out is data trial the this and of study round in supporting on BAXXXX of anticipate program, track patients cancer. X year. The BAXXXX we CAB-ADC patients consisting To IIT the with also Phase platinum-resistant are with our second ovarian we interim in XX half

antibody Phase BAXXXX. our our for to briefly CAB-CTLA-X I'd talk Now, trial X/X like about

trial in tumors nivolumab. safety monotherapy As BAXXXX a as and being reminder, is to and trial Phase planned. known of CTLA-X X/X be tolerability to and conducted in evaluate we the is progressing with will responsive treatment, The in combination

the DLT observation period mg/kg at cleared reported. fourth combination a mg/kg XXX X No DLTs for with that Last cohort were in mg was quarter, shared dose nivolumab. X or I the of of

of in As on treating in X part mg/kg X as for a are mgs nivolumab readout of are patients combination half we the or fifth at today's in year. of update, a Phase second data cohort X with the and monotherapy mg/kg track XXX this or

on initiation in of our second study remain commence the of also this BAXXXX year. Phase We X to for track half the

the the engager in in CAB Finally, In cell complete year. of our patient X we received on We for potentially clearance Phase the study the adenocarcinoma. first advanced BAXXXX. anticipated X CAB-CDX, first-in-class readout dual current the bispecific anticipate T IND FDA next our data treatment quarter, of for quarter first Phase CAB-EpCAM, to or antibody, with

in selectivity dual-CAB clinical to due to view promise antibody studies the the other XXX-fold non-CAB relative combined of candidates, index preclinical variants improvement Similar much product stage an design. three therapeutic the the in demonstrating in the CAB of our to this over holds vivo

adenocarcinoma that lung, common need colon, tremendous and most prostate. can subtypes unmet of the breast, Several we include pancreas, that potentially of address have

still progress also ADC CAB including through IND-enabling we XXXX. studies, in for antibodies, and next-generation and bispecifics additional several BioAtla and through continues XXXX to anticipate potentially IND submissions candidates candidates

the of important the Congress, Cancer exposure Lung and company AACR, related BAXXXX. upcoming will online the and which has poster of to abstract at latter With since Sarcoma the ASCO, presentation ongoing and communications, accepted include ESMO of an European March, publication Congress, Rare respect analysis nine to including response recent Cancers the

have these Additional meetings, accepted. are been as they upcoming updated submitted for abstracts several and will be

that, XXXX to the call review to I quarter Rick Rick? like over With financials. the would turn first to of now

Richard Waldron

you, Thank Jay.

As XX, million million we of March $XXX.X XX, December cash in cash equivalents and XXXX, as of to $XXX.X XXXX. compared had

cash all to will cash programs equivalents into be product CAB We and current sufficient development operations, ongoing planned expect including fund XXXX.

a reminder, control market all the Europe rights product As US, CAB in we Japan. and

commercial in commercialization includes extend while could territories Our cash to the certain biopharmaceutical selective and milestones provide also product and exploring for royalties cash global in that value advancing preparations additional companies our development business upfront stockholders. regulatory other collaborations opportunities with create generating to licensing or runway markets approval of upon and through us key rights by strategy

quarter XXXX, the compared XXXX. loss we to the of net a ended $XX.X million XX, period of loss $XX.X net in first a same of million reported For March

million XX, was million expenses $XX.X to our by development driven XXXX clinical period XXXX. and were same increase compared Research in for preclinical development for March $X.X efforts. product million the The and quarter ended $XX.X of the primarily first

and remain we clinical to quarter-to-quarter generally invest increase to as programs. expenses R&D continue to product and activities our expect candidates in We from R&D advance our our variable

attributable in and million in $X.X General various to March XXXX same for was a for million the million for $X.X XXXX period administrative expenses XX, period. compared the ended The decrease to the first quarter XXXX. were $X.X expenses change

our our candidates, increase advance our to intellectual expenses We and activities candidate a G&A our expect for to support BAXXXX, company. development satisfy property moderately requirements portfolio, of support product product pre-commercialization public as focused

period net the XX, for ended operating in in activities operating compared for XXXX, same of Net months cash to was in $XX.X three million used March $XX.X cash used million XXXX. the activities

payable compared net XXXX in for period and of in The first decrease in cash the in due to in the XXXX. the in is three XXXX months decrease used activities accrued expenses accounts to in a an primarily accounts operating period increase payable same

to back Jay. now And

Jay Short

Thank you, Rick.

the continue results to-date and efficacy We have support made cumulative are platform. from proprietary safety the that and differentiated our preliminary CAB to our both pleased with progress we

is excited We the eager half and in more year. updates are the cell continue Phase addition of emerging the are refractory compelling this studies clinical with and non-small data that anticipated cancer treatment advancing in frequent with of providing clinical X UPS the regimens dose-intensive to the second lung and

by multiple we assets promising in are and inflection the encouraged our months. milestones indications, several value-creating other CAB remain also key We to and execution continued well several points cancer poised reach and the next of

confident have shareholders impact the of goal of we feel need with patients that high our worldwide. unmet remains about and will the indications BioAtla future medical pursuing significant for

we will back that, turn to to questions. With the your operator take it

Operator

sir. you Thank

comes the session. a And proceed your with of [Operator conducting question. line the Please question from JPMorgan. with first be now will We Instructions] Cheng Brian question-and-answer

Brian Cheng

question. afternoon me. from taking couple Good guys. for my A Thanks

ahead that Thank then multiple year, And in a you. of cadence data the update across about have this we those think in each of of I How data couple it have updates? a second programs number second of follow-ups. the you half. should the of data half Looking into interim seems the

Jay Short

Yes, Jay and this question, for thanks your is Brian.

the readouts ones. to see of -- let's we'll think the point, would think key but some to I expect to of be AXL are expecting and a I guess ovarian expect best this say, is that ahead see RORX, -- the lung was those the than, earlier I the readouts this at

of the in well. giving be in somewhere And And on of progress terms of CTLA-X then terms reports will UPS, there progress in of area reports of general -- sarcoma -- in also as course, course, be we'll, leiomyosarcoma.

then and of Phase Phase kind later, the the a X and updates, a little -- saying a off in So, couple X CTLA-X like follow-up be right? of may completing kicking there's study. One

intent. our that's with the happen So, would Same lung. AXL

with then of kicking FDA last portion tied Here's the in portion a X meeting -- and off our or the off conference that. describing kicking X and data, hopefully the followed part of by feedback X Phase Phase

So, it, hopefully, that of a sense Brian. gives you

Brian Cheng

on potentially was thoughts to to for program decided you or Phase what's of to guess, your that on regimen the Great. if non-small the value on part is latest FDA? that helpful. the second X AXL half, cell, the have XI? you design part question squamous, I part the think more combo the then in That And whether whether with non-squamous have is, focus you X pivotal single trial agents? more data the And I And trial your protocol second the part for extent, revisit with in frequent looks versus will better

Jay Short

ask we're that to actually the going answer So first the say I Philly, non-squamous. focus I'm questions though non-squamous now, of decided going the section. rest one Philly in think off, the this we're just can more -- I think we've But I learn even forward, the to on side, but this there's focus to going on to on potentially to squamous

Philippe Martin

Yes. Thank Jay. you,

the So around the of the clearly, in will this the quarter. study of conversation focus be this of think, I terms with end the FDA design,

could might haven't comparator -- we'll and still it or single go decide go -- PFS a whether ORR on tolerable based We it study feedback, an readymade primary with also the landed their a but endpoints against with our docetaxel endpoint. a endpoint, or which to arm be be

later we'll monotherapy, So this year. data the we're we'll on getting but on in post-meeting decision for with Currently, that make focusing be FDA. more combo the

which able whether as we'll go monotherapy. combo be So the decision focus will only a on to to well, make with

-- not XQXW, to FDA, should to that have forward it we discussing with And decide to The sponsor dose would doses we or your the required. with last move will be be is to about then dose no, question selection let with. which

dosing So should the with profile QXW the risk better see replace could level a which benefit the just XQXW we arm, with XQXW regimen.

Brian Cheng

If with does you're approved you. out great. you're correlate be engagement dose more CAB-CTLA-X, How you're target the Okay. market in currently squeeze the one the space? seeing the that in XXX dosing can agents with that the that Thank to CTLA-X would seeing now on that I CAB-CTLA-X

Jay Short

with Well, we've a do we and ipilimumab, done lot a lot of of so work comparisons.

is when we think to antibody comparable believe start our doses. about that ipi most to So you these

in Of comparison. and so their course, will and the part different PK nuances was antibodies be most different all there our they're and because But similar forth. a very but origin for -- of sequence,

general nice think the with of study. of at caveat that's some I end a So PK guideline the alignment the

Brian Cheng

today. Thanks Okay. question, taking for my

Jay Short

Yes.

Operator

with question next of from the And Jefferies. the line Shi Kelly comes

Unidentified Analyst

Kelly This is is Jefferies. to everyone. Dave traveling from Hi, Asia.

behalf here I'm on So of her.

question last were March, in you enrolled patients update In one Just mentioned cohort. for six LMS quick me. there in

are expect XX pace XX --? to new then? how any on wondering to when comment you do Just added an many enrollment? patients And patient complete since And of

Jay Short

Yes. believe on I update the completed but don't an have think available and in be there. we it's half second going will to -- I be readily additional don't patients, we

there's indication timely in won't report nuance in have other on But have being that any don't terms fall. on that it. no the that I know, Philly, to So if we be it able of you

Philippe Martin

based to No, XX%. we're XX patients But of closer be than I on more second pace the we're on half, enrollment, to schedule, on XX% think, might it the in target. XX

Unidentified Analyst

question. Okay. Thank you for taking my

Operator

with question line next Kaveri from comes the And your with Pohlman question. BTIG. the of Please proceed

Kaveri Pohlman

my Yes. Good evening. taking for Thanks questions.

durability you're cell late-line see cancer, would to the what's you clinically these non-small in data collecting? What can meaningful lung us here? tell bar for For the be from patients

Jay Short

Philippe, a Yes. we've you And that grab before, this I question. should think that's since discussed good No, one.

Philippe Martin

Yes.

failed, dosing after gemcitabine and of PD-X will but then generally remember, have meaningful have failed the what failed be would first docetaxel or in they patients that that. think only chemo that at round are patients patients not I be that

So response four Durability they above are months refractory. positive. would highly anywhere be of

had As we'll led believe we plus. targeting be the that X we said us able months before, And data are to we that. achieve latest recorded to

Kaveri Pohlman

And forward with line. susceptible it. just line? helpful. non-squamous. believe Got type was regimen you're MMA less moving squamous the is I treated in that respond you to to it wondering, I taxane just with I That's Does make in first that mentioned believe based late

Philippe Martin

think that's case. don't the I

-- squamous able I new think move with it's were not to not moving we're because squamous patients. just we

patient we don't point. So how this at will this know respond

squamous data that warning generate to squamous patient decide with need we'll to further before patient. we start So go or

Jay Short

patients just into study. the a lot non-squamous more Yes. coming There's

Kaveri Pohlman

Got And one on that LMS UPS last plan test frequent regimen doing other and before one just way it. have you're besides to to maybe move the you the types sarcoma for LMS. and you more you decide forward? Do UPS there

Jay Short

March our I in this -- we're X LMS of it Well, on strategies mentioned move I Obviously, -- studies had we're going want indications, and an the that think that is, the because March the UPS lot going be end -- we on. we'll mean, of a also Phase data I to we'll of we to drive doing be as wait think across have looking that. lot around call awful down line,

So over prioritizing which we'll we in fall. be prioritize at that will time the on ones others

couple some but believe, data, be of sarcomas, do bone still getting passed several others our types And but And add. a well other sarcoma -- as there of as LMS we already criteria. have to the so will them ultimately,

sarcomas be opportunities. to I mean I that's which other in those ones indications have be first, think but we we that the and I very some carefully also, to great go we'll load at and yet think because actually will fall. we looking when But have determined was, to balance large

Kaveri Pohlman

you. That's helpful. Thank

Operator

from Securities. of next [Operator JMP your with question with the Benjamin Please the proceed Instructions] line And comes questions. Reni

Reni Benjamin

about kind us on the can take assay now, your taking its the Maybe commercialization as off, And liquid to but it confined I start how questions. development right that guess, across latest know we could through you thoughts the appears just all Thanks program? for I does just get, use word of for potential is biopsy programs. be to this further be to, something and this, the think to the this part as further ready fine-tuned of expanded?

Jay Short

to want handle one? Philippe that or Eric, who just

Philippe Martin

wants Yes, I'll add more. then to start and Eric

confined we cell data. not it's So a are biopsy lung developed have to And non-small we currently AXL generating what as liquid for well.

that's that of we testing every them the patient obviously biopsies. we because liquid the IHC in only have also are them So testing the intercriteria, for efficiency we're study, for but current the

of the the from CTC So data we'll the able have we all part data results all IHC patients. enroll to study. the be the correlate But once to we this first

we're discussed to we've data and we ongoing before, it's moving both we RORX this to we that and were are within been identify the assays. in difficulty because some that CTC waiting for AXL as had prioritize So in more and generate able patients melanoma and now using positive assay just

is our going attachment. future, So with liquid CTC now, to right the should perform, assumption IHC, to could continue in the we're biopsy switch we but

Reni Benjamin

it. Got

coming Okay. in And you out the I half. second think readouts have several

You sense of mentioned anticipated XX you the to anything for on lung? a worth now. about patients the XX that's be top might And us head of might my coming I patients worth we patients for the enrollment else give Can right LMS. trends, non-small missing readout from not many ovarian, how for see to current data just worth XX based

Jay Short

an estimate? you'll AXL to go as ahead one lung, update give the you want that Philippe, on Yes, on

Philippe Martin

Yes.

the then patients QXW, QXW, and XQXW patients dosing XX target XX with lung, and to XX on is a So patients combo approximately patients regimen. have XQXW XX with

So target the that that's the cohort. involved we've already ourselves. QXW for We've set

the annulling XQXW the currently XQX and are We cohorts.

-- the lung AXL our cater. non-small that's So for target that's cell

Jay Short

described -- we we're Yes. regimens? And XX few But frequent good dose-intensive a a where what to shy be exactly get feeling few I certainly, more a we'll of Philippe patients the think happen targeting. hit that. whether on

Reni Benjamin

if What thinking right? it about And about BAXXXX, BAXXXX? for that was I'm

Jay Short

Yes.

add of But the sense enough that to FDA how want with do us nice bit. discussions that? with BAXXXX. a -- Philippe, would I go of to with end going the discussions our be more intensity, in to the in we're behind but dose frequent regard certainly, things. to year think you give a we of future hopefully little the to at And to terms like

Philippe Martin

Yes.

XX is XX in and some might it number maybe above XX of shy other the we're our is be cohorts, the the monotherapy to approximately, couple patients of going. by Obviously, QXW patients are or so a have target, looking target So XX year. patients combo or the end it the target of but and is QXW there XQXW. These current

Reni Benjamin

guys. Thanks Yes.

Jay Short

I also do And that try also To in when hit out, just one read is, we with be It's would just third early is to meetings December, we're the potentially year we're give we all our decided. for AXL. to things it's of of an earnings at or depending a upcoming getting the little to to those mean at quarter. more conference of add, have push in that kind issue the for it have a sense if I or yet precision. data these than in of RORX, going those into -- the question early that January

please, So mind. that in keep

Reni Benjamin

Got Thank much. it. you very

Operator

of the He with from with the your H.C. comes And next question proceed line Arthur question. Please Wainwright.

Arthur He

Wainwright. Good Jay Rick. Arthur is And my thanks question. H.C. taking This afternoon, Hi. for from and

the So I lung BAXXXX cancer. data just BAXXXX wanted to and follow-up on updating the

for and the decision to to So potentially? besides for data, looking those the choose pivotal ORR, make dosing the optimal at other criteria presumably study the what when look safety you're the you you

Jay Short

mentioned already about, targeting And other got six care greater. I I think and that duration we'll something a ultimately, we feature. that's months Well, to Philippe have what and there of think and we're -- be key And I the that's think, we or at. looking you've response, already

we've therapies we're to with that of open what other positive, that we position we arriving in some date. could data a looking coming strong efficacy these think with PD-X and really there Obviously, of very some Even seen -- to choices. don't -- are groups obtained new could patients are still failure have the any the have encouraged -- I actually think got for already in we up the what especially patients we for been with that be XX% we potentially XXXX, in and really

Arthur He

BAXXXX dose that. for program, part. looking from Great. escalation when the initial Okay. Thanks data the And the we're for for

monotherapy the get we the for could both see the data? combo how for So RPXD and idea when the we about

question the study? expansion you another together? And are straight and planning going Or combo are go study, including combo mono to for to is the for you

Jay Short

Yes. Philippe, go ahead.

Philippe Martin

Yes.

ipilimumab in mean, has our is used focus been combination generally used So combination, PD-X. okay, how with I the mostly or is that's yes, because

So said, that's we are being monotherapy as That focus. at our looking data primary well.

of looking selection, efficacy we'll efficacy the or PK terms at safety the certain In be dose in as as characteristics well at -- we're and at. are we've that also the we but treated, markers that looking patients at dose looking

data. it's assessment right, for be to the us expansion another will the forward. will choose go lead doses go two of reserve data that So to of with again, the focus combo, to We or primary one mono and but combo our

Arthur He

ovarian the Philippe. And the as regimen well sarcoma. criteria you dose -- data and dosing for study? Thanks exclusion remind the good question the my intensive cancer the And either more us a is the the optimization way you ovarian Thanks. Is a for there lung the study. -- last if cancer from see do study? on from you. cancer inclusion Got Could and to for the that

Philippe Martin

Yes.

and platinum So at intensive translating well. failure dosing more to currently, the the patients, generate with these that are tolerated indications it's see the We and and as well is dose efficacy other -- looking we're be in indication regimen PD-X the we'll that combination inhibitor. more

taking two intensive move to able we take forward problem may forward, forward we the of study that study case would to We with regimen. be regimen. a a doses the dosing would in be So but most have with wouldn't registration likely ovarian, decide the the dosing more higher

Arthur He

taking and congrats question Thanks. quarter. progress my for Okay. the this on Thanks

Philippe Martin

you. Thank

Jay Short

Thank you.

Operator

no And questions. time, further there at this are

closing the comments. Now, over turn to for any to I'd like back Jay floor

Jay Short

thank we're of up for couple looking really and of and to to readouts forward next their want today, a lot everyone attention I Well, quarters. time coming in the

So you. thank

Operator

This thank you, does conclude today's And conference. everyone.

have Thank this disconnect participation, your you and at may your day. lines You a time. for great

BioAtla (BCAB) 11 May 232023 Q1 Earnings call transcript